Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles
Loading...
Date
2022
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Tuberculosis (TB) remains one of the deadliest communicable dis-
eases caused by Mycobacterium tuberculosis (Mtb) since its discovery in
the 1880s (Cambau and Drancourt, 2014; Singh et al., 2020). Over 1
billion mortalities have been recorded to date due to TB, and it was the
leading cause of death from a single infectious agent before the COVID-
19 pandemic, with an estimated 10.4 million new cases and an average
of 1.7 million deaths yearly (Gagneux, 2018; Barberis et al., 2017; Scriba
et al., 2020; Allu ́e-Guardia et al., 2021; Organization, 2021). Further,
about 25% of the world’s population are latently ill or infected,
providing a substantial pool for future cases of active TB (Gagneux,
2018). The World Health Organisation (WHO) reported that in 2019 an
average of 10 million new cases were recorded, with 1.2 million cases
being children and an estimated total of 1.4 million mortalities (Orga-
nization, 2019).
Description
Keywords
Tuberculosis, Nanoparticles, Alveolar macrophages, Mycobacterium tuberculosis, Therapeutics
Citation
Khoza, L. J. et al. (2022). Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles. International Journal of Pharmaceutics, 622,121893. https://doi.org/10.1016/j.ijpharm.2022.121893